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Discontinuation of in vitro fertilisation (IVF) cycles has been part of the radical 
transformation of healthcare provision to enable reallocation of staff and resources to deal 
with the COVID-19 pandemic. We sought to estimate the impact of cessation of treatment on 
individual prognosis and United States population live-birth rates. 
Design 
Data from 271,438 ovarian stimulation UK IVF cycles was used to model the effect of age as 
a continuous, yet non-linear, function on cumulative live-birth rate. We recalibrated this 
model to cumulative live-birth rates reported for the 135,6733 stimulation cycles undertaken 
in the USA in 2016, with live-birth follow-up to October 2018.  We calculated the effect of a 
one-month, three-month and six-month shutdown in IVF treatment as the effect of the 
equivalent increase in a woman’s age, stratified by age group.  
Results 
The average reduction in cumulative live-birth rate would be 0.3% [95% CI: 0.3, 0.3], 0.8% 
[0.8, 0.8] and 1.6% [1.6, 1.6] for a one-month, three-month and six-month shutdown, 
respectively. This corresponds to a reduction of 369 [95% CI; 360, 378), 1,098 [1071, 1123] 
and 2,166 [2,116, 2,216] live-births in the cohort, respectively. The greatest contribution to 
this reduction was from older mothers.  
Conclusions 
We demonstrate that the discontinuation of fertility treatment for even 1 month in the USA 
could result in 369 fewer women having a live-birth, due to the increase in patients’ age 
during the shutdown. As a result of reductions in cumulative live-birth rate, more cycles may 




Discontinuation of the 2.5 million in vitro fertilisation (IVF) cycles performed annually 
(Fauser, 2019), has been part of the radical transformation of healthcare provision to enable 
reallocation of staff and resources to deal with the COVID-19 pandemic. As of 14 March 
2020 the European Society for Human Reproduction and Embryology (ESHRE), the 
American Society for Reproductive Medicine (ASRM), and other international professional 
bodies all recommended that assisted reproduction treatments should no longer be 
commenced, with national authorities aligning to ensure rapid cessation of treatment and 
prevention of overburdening healthcare systems. The success rates of infertility treatment are 
however acutely time sensitive, with progressive monotonic declines with advancing 
maternal age from age 34 years (Smith, et al., 2015). With most cycles starting in women 
older than 34 (e.g. in the US ~61% >35years and mean age at ovarian stimulation 35.5 in the 
UK and 38.0 in Japan (Ishihara, et al., 2020), it is likely that a temporary shutdown of IVF 
treatment could cause a reduction in the number of IVF live-births. Even as clinical services 
are recommenced, they are likely to be at differential rates depending on local resources and 
policies, with the potential for variable delays in treatment. The purpose of this short 
communication is to estimate the extent of such a reduction in individual prognosis and 
population live-birth rates. 
 
Methods 
We used data from the Human Fertilisation and Embryology Authority (HFEA) on IVF 
treatment in the UK to model the effect of age on cumulative live-birth rate. The HFEA 
dataset recorded age in years, without groups, which allowed us to model the effect of age as 
a continuous, yet non-linear, function (Smith, et al., 2019, Smith, et al., 2015). This model 
was then recalibrated to the most recent cumulative live-birth rates reported for the USA by 
 
 
the Centers for Disease Control and Prevention (CDC) as detailed in the latest Assisted 
Reproductive Technology Fertility Clinic Success Rates Report (CDC, 2019).  The 
development model incorporated 158,197 women undergoing 271,438 ovarian stimulation 
cycles for IVF in the UK between January 1, 2003 and December 31, 2010, with follow-up of 
all embryo transfers until June 30, 2012. The recalibration model incorporated the 135,673 
stimulation cycles undertaken by the 448 clinics in the USA that were commenced between 
January 1, 2016 and December 31, 2016, with inclusion of all embryo transfers that occurred 
within 12 months, and live-birth follow-up to October 2018 (CDC, 2019). The cumulative 
live-birth rate was defined as the probability of a live-birth from an ovarian stimulation 
encompassing all subsequent fresh and frozen embryo transfers from that stimulation. In the 
US this was time limited to an embryo transfer occurring within 12 months. In the UK live-
birth was defined as birth of one or more infants born alive after 24 weeks gestation surviving 
more than one month, while in the US live-birth was defined as birth one or more infants with 
any sign of life (CDC, 2019). Full details of the model and assumptions are given in 
supplementary material. We calculated the effect of a one-month, three-month and six-month 
shutdown in IVF treatment as the effect of the equivalent increase in a woman’s age, 
stratified by age group.  
 
Results 
Our model showed the decline in cumulative live-birth rate is observable from 33 years of 
age, for women using their own oocytes (Supplemental Figure 1). Table 1 shows the 
estimated effect of shutdowns of various duration on the cumulative live-birth rate, and the 
estimated reduction in number of IVF live births in the US CDC cohort, stratified by age. The 
average reduction in cumulative live-birth rate would be 0.3% [95% CI: 0.3, 0.3], 0.8% [0.8, 
0.8] and 1.6% [1.6, 1.6] for a one-month, three-month and six-month shutdown, respectively. 
 
 
This corresponds to a reduction of 369 [95% CI; 360, 378], 1,098 [1071, 1123] and 2,166 
[2,116, 2,216] live-births in the cohort, respectively. Older mothers would contribute 
disproportionately to this reduction, with a one month delay resulting in 2.9% [95% CI; 2.8, 
2.9] fewer live-births from 41-42 year olds as compared to 0.35% [95% CI; 0.3, 0.4] fewer 
births from women ≤35 years old.  
 
Discussion 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the coronavirus disease 
2019 (COVID-19) pandemic has been responsible for the transformation of infertility service 
provision. We demonstrate that the discontinuation of fertility treatment for even 1 month in 
the USA could result in 369 fewer women having a live-birth, due to the increase in patients’ 
age during the shutdown. There was evidence of divergence on the overall contribution to 
live-births with increasing maternal age, with older women greatest affected by delays in 
treatment.  
 
Due to the pre-existing legal regulations and new HFEA guidance introduced in 2015, the 
equivalent UK data for cumulative live-births could not be obtained. We sought to recalibrate 
our model for the most recent population dataset reporting cumulative live birth outcomes 
with an extended follow-up to allow for frozen embryos to be included in the analysis (CDC, 
2019). By using cumulative live-birth from a single ovarian stimulation cycle, thereby 
allowing for the transfer of fresh or frozen embryos, and by accounting for multiple births as 
a single event, differences in clinical practice between the UK and US will have been 





Recommencement of infertility services needs to occur soon, as accommodating social 
distancing working patterns and other SARS-CoV-2 transmission risk mitigation measures 
are likely to impact further on capacity facilitating further delays. Whether the rapid rises in 
US unemployment and / or fear of engaging with the healthcare sector or concerns regarding 
pregnancy and perinatal outcomes despite reassuring data (ACOG 2020), will further 
contribute to a reduction in clinical activity on reopening is unclear. Accurate quantification 
of the overall impact will not be available for several years due to the timelines of CDC, and 
equivalent data custodians in other countries (e.g. HFEA in the UK) reporting or making data 
available on cumulative live-births, and we acknowledge that this may be less or greater than 
modelled here. Further national or local SARS-CoV-2 epidemics, or even another pandemic, 
are possible, and that would mean our results were an underestimate and the long-term 
consequences considerable. The personal and societal toll of the cessation of infertility 
treatments, despite being recommended for only a short period of time by both ASRM and 
ESHRE, is likely to have an unrecognised persistent emotional and economic impact for 
many patients and staff. Particularly as the re-initiation and regaining of patient confidence in 
healthcare services may take substantially longer than the simple reversal of a professional 
bodies edict. Irrespective of the drivers, more cycles may be required to overcome infertility 
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Estimated changes in cumulative live-birth rates and number of live-births associated with shutdown 
of IVF treatment, by age of patient, in sample of 135,673 IVF cycles representing one year of 
treatment provision. 
Age group (years) < 35 35-37 38-40 41-42 >42 
Number of cycles per year* 52,428 28,996 28,287 14,358 11,604 
Without shutdown      
Estimated cumulative  
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* Based on 2017 figures from CDC report 
